FHI:NYSEFederated Hermes, Inc. Analysis
Data as of 2026-04-03 - not real-time
$57.81
Latest Price
3/10Risk
Risk Level: Low
Executive Summary
Federated Hermes is trading near $57.8, comfortably above its 20‑day ($56.5) and 50‑day ($55.3) simple moving averages, and the MACD histogram remains in bullish territory, indicating continued upward momentum. The RSI sits at roughly 59, suggesting room for further upside before overbought conditions emerge, while the nearest support at $53.3 and resistance at $58.5 frame a tight trading range. Earnings have beaten expectations, driven by a 13.7% revenue growth rate, a robust gross margin of 68% and an impressive ROE of 34%, supporting the company’s high profitability profile. A dividend yield of 2.34% with a modest payout ratio of 26% appears sustainable given strong operating cash flow and a healthy balance sheet. Valuation metrics are compelling: the trailing P/E of about 11 is well below the industry average of 16.5, and the price‑to‑book of 3.5 reflects a reasonable premium for a high‑quality asset manager.
Risk is muted: beta under 1 (≈0.73) points to lower market sensitivity, 30‑day volatility around 22% is moderate, and the stock enjoys ample liquidity with stable volume. The company’s geographic exposure is primarily U.S.‑centric, limiting currency risk, while regulatory risk remains medium given the oversight of the financial services sector. Overall, the combination of bullish technicals, solid fundamentals, and an attractive dividend makes FHI a compelling case for investors seeking a blend of growth and income.
Risk is muted: beta under 1 (≈0.73) points to lower market sensitivity, 30‑day volatility around 22% is moderate, and the stock enjoys ample liquidity with stable volume. The company’s geographic exposure is primarily U.S.‑centric, limiting currency risk, while regulatory risk remains medium given the oversight of the financial services sector. Overall, the combination of bullish technicals, solid fundamentals, and an attractive dividend makes FHI a compelling case for investors seeking a blend of growth and income.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish technical setup but price near short‑term resistance
- Recent earnings beat supporting momentum
- Attractive dividend yield with sustainable payout
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Significant valuation gap versus DCF fair value
- Strong cash generation and low leverage
- High ROE and consistent earnings growth
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Sustainable dividend stream
- Stable sector fundamentals for asset managers
- Potential price correction if valuation narrows excessively
Key Metrics & Analysis
Financial Health
Revenue Growth13.70%
Profit Margin22.40%
P/E Ratio11.3
ROE34.30%
ROA14.89%
Debt/Equity36.17
P/B Ratio3.5
Op. Cash Flow$297.3M
Free Cash Flow$384.2M
Industry P/E16.6
Technical Analysis
TrendBullish
RSI59.3
Support$53.29
Resistance$58.48
MA 20$56.50
MA 50$55.34
MA 200$51.71
MACDBullish
VolumeStable
Fear & Greed Index78.8
Valuation
Fair Value$124.53
Target Price$56.14
Upside/Downside-2.88%
GradeUndervalued
TypeBlend
Dividend Yield2.34%
Risk Assessment
Beta0.73
Volatility22.01%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.